Skip Navigation


European Heart Journal Advance Access originally published online on June 6, 2007
European Heart Journal 2007 28(12):1405-1406; doi:10.1093/eurheartj/ehm168
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/12/1405    most recent
ehm168v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kaul, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaul, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?

Padma Kaul

Department of Medicine, University of Alberta, 7721 Aberhart Center-I, 8440-112 Street, Edmonton, Alberta, Canada T6G2B7

Corresponding author. Tel: +1 780 407 8680; fax: +1 780 407 8368. E-mail address: pkaul@ualberta.ca

This editorial refers to ‘Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin’ by P. Lindgren et al., on page 1448

The first 10% of the full text of this article appears below.

The use of statins in the management and prevention of coronary artery disease has been shown to be associated with significant reductions in the incidence of major adverse events, including death, myocardial infarction (MI), and stroke.1 Clinical practice reflects the impact of this evidence: between the EUROASPIRE I and II surveys, reported rates of statin use in Europe increased from 18.5% in 1995–96 to 57.7% in 1999–2000 among patients with coronary heart disease.2 Despite this increase, over 40% of the patients had failed to reach targeted cholesterol concentrations. Four recent trials have examined the impact of higher dose statins compared with standard dose statins in meeting more stringent low-density lipoprotein (LDL) cholesterol goals and thereby reducing cardiovascular outcomes.3 The most recent of these, the Incremental Decrease in End Points Through Aggressive Lipid . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Peter Lindgren, Jennifer Graff, Anders G. Olsson, Terje J. Pedersen, Bengt Jönsson, and on behalf of the IDEAL Trial Investigators
EHJ 2007 28: 1448-1453. [Abstract] [Full Text]